HOTH vs. PTIX, VCNX, ATXI, FWBI, XBIO, CVKD, AIMD, ADXS, OGEN, and HILS
Should you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Protagenic Therapeutics (PTIX), Vaccinex (VCNX), Avenue Therapeutics (ATXI), First Wave BioPharma (FWBI), Xenetic Biosciences (XBIO), Cadrenal Therapeutics (CVKD), Ainos (AIMD), Ayala Pharmaceuticals (ADXS), Oragenics (OGEN), and Hillstream BioPharma (HILS). These companies are all part of the "pharmaceutical preparations" industry.
Hoth Therapeutics (NASDAQ:HOTH) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
Hoth Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 241.88%. Given Hoth Therapeutics' higher possible upside, research analysts plainly believe Hoth Therapeutics is more favorable than Protagenic Therapeutics.
Hoth Therapeutics received 65 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
Hoth Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks.
7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are held by institutional investors. 3.3% of Hoth Therapeutics shares are held by company insiders. Comparatively, 37.0% of Protagenic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Protagenic Therapeutics' average media sentiment score of 0.46 beat Hoth Therapeutics' score of 0.00 indicating that Protagenic Therapeutics is being referred to more favorably in the news media.
Hoth Therapeutics' return on equity of -76.28% beat Protagenic Therapeutics' return on equity.
Summary
Hoth Therapeutics beats Protagenic Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Hoth Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hoth Therapeutics Competitors List
Related Companies and Tools
